In a more recent study investigating PCa death as the clinical endpoint in a large cohort of patient-derived TURP tissue (n = 385), a prognostic model was built on 6 methylation biomarkers (see Table 1) including PITX2, and was able to improve on the sensitivity of the Cancer of the Prostate Risk Assessment (CAPRA) score to predict aggressive PCa at 10 years follow-up with an AUC of 0.74 (Table 1) [98]. The gene discussed is PITX2; the disease is posterior cortical atrophy.